In this second patient case video from BREAST CANCER CONNECT, Prof. Maria Vittoria Dieci delves into the continuation of a patient case with ER+/HER2- metastatic breast cancer initially presented in our first video of this series.

Throughout this journey, we'll explore what to expect after prescribing elacestrant and take a closer look at patient-reported outcomes in the EMERALD trial.

Catch up on the first video to hear Prof Francois-Clement Bidard discuss how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer.

Clinical Takeaways

  • PROs results demonstrating no difference between treatment arms in the EMERALD trial, support elacestrant as a clinically meaningful option in this setting

  • Elacestrant has a manageable safety profile

  • If a patient progresses on elacestrant, the choice of subsequent therapy line should be based on multiple factors, including sensitivity to prior treatments, disease burden, and tumour biology. In this context, ADCs represent a new option

Maria Vittoria Dieci, MD, is Associate Professor at the University of Padova, vice-director of the Specialization School in Medical Oncology at the same University and attending physician at the Division of Oncology 2 of the Istituto Oncologico Veneto in Padova. She specialised in Oncology in March 2012 at the University of Modena. From May 2012 to November 2013 she completed a 18-month-research experience at the Translational Research Unit (INSERM U981) of the Gustave Roussy Institute (Villejuif, France), and obtained the “Diplome Universitaire Européen en Recherche Translationnelle et Clinique en Cancérologie”. Since November 2013 she has been conducting research and clinical activity in the field of breast cancer at the University of Padova / Istituto Oncologico Veneto IRCCS.

She is panelist of the Breast Cancer Guidelines by the Italian Association of Medical Oncology. Prof Dieci’s research production from 2008 up till now consists of more than 140 papers in peer-reviewed journals.

Prof. Maria Vittoria Dieci has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Pfizer, Novartis, Roche, Exact Science, Daiichi Sankyo, Gilead, Seagen.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Medical Educational Grant from Menarini Stemline Oncology.

Meet the experts

Other programmes of interest

Video
Oncology 
The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Experts
Assoc. Prof. Umberto Malapelle
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
Advanced renal cell carcinoma: Managing a long-term durable response

Maximising outcomes for patients with advanced RCC 

Experts
Prof. Michael Staehler
Endorsed by
Urobel VZW | ASBL
  • clock 15 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Eisai Europe Limited.
Other

Episode

1

of 1

episode
Oncology 
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.